Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma. (PubMed, Int J Urol) - Oct 21, 2026 - "Adjuvant nivolumab therapy may provide comparable oncological outcomes between BC and UTUC. Baseline eosinophil count was an independent prognosticator for DFS. The incidences of adrenal insufficiency and hypophysitis appeared higher in our real-world data. Clinicians should recognize these irAEs due to nonspecific symptoms and considerable variability in time of onset."
Clinical • Journal • Retrospective data • Bladder Cancer • Endocrine Disorders • Genito-urinary Cancer • Nephrology • Oncology • Renal Disease • Solid Tumor • Urothelial Cancer
|
|
Akihiro Matsukawa; Ichiro Tsuboi; Kazuma Tsuboi; Keiichiro Mori; Kensuke Bekku; Kohei Ogawa; Koichiro Wada; Kosuke Iwatani; Motoo Araki; Satoshi Katayama; Shingo Nishimura; Shota Inoue; Takafumi Yanagisawa; Takahiro Kimura; Takehiro Iwata; Tatsushi Kawada; Tetsuya Nakada; Tomoaki Yamanoi; Tomofumi Watanabe; Wataru Murao
|